A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection
The purpose of this study is to compare the drug levels, immunogenicity and safety of Nivolumab Process D to Nivolumab Process C after complete resection of stage IIIa/b/c/d or stage IV melanoma.
Melanoma
DRUG: Nivolumab
Area under the concentration-time curve in one dosing interval (AUC[TAU]) (336 h), Over the dosing interval at Week 1 and Week 17
Maximum Observed Plasma Concentration (Cmax), Over the dosing interval at Week 1 and Week 17|Observed serum concentration at the end of a dosing interval (Ctau), Over the dosing interval at Week 1 and Week 17|Time of maximum observed plasma concentration (Tmax), Over the dosing interval at Week 1 and Week 17|Number of Participants With Positive Anti-Drug Antibodies (ADAs) and Neutralizing Antibodies (NAbs), Through Week 51 Day 1|Number of Participants With Serious Adverse Events (SAEs), Up to 65 weeks|Number of Participants With Adverse Events leading to Discontinuation, Up to 65 weeks|Number of Participants With Adverse Events (AEs), Up to 65 weeks|Number of Participants With Clinically Significant Laboratory Abnormalities, Up to 65 weeks|Number of Participants with AEs leading to death, Up to 65 weeks
The purpose of this study is to compare the drug levels, immunogenicity and safety of Nivolumab Process D to Nivolumab Process C after complete resection of stage IIIa/b/c/d or stage IV melanoma.